Table 2 The pathways that were found to be notable in at least one cancer analysis. The second column shows the number of cancer types in which the pathway was found to be notable. The pathways are ranked by that column. The third column contains an “N” if the pathway was found to be notable in the pan-cancer analysis and it contains an “S” if it was only found to be significant in the pan-cancer analysis. The fourth column shows the p-value in the pan-cancer analysis
From: Pan-cancer analysis of TCGA data reveals notable signaling pathways
Rank | Pathway | # cancers | Pan_cancer | p-value |
|---|---|---|---|---|
1 | Focal Adhesion | 5 | N | 5.99E-06 |
2 | Cytokine-cytokine receptor interaction | 5 | S | 0.006 |
3 | PI3K-Akt signaling pathway | 4 | N | 1.01E-05 |
4 | Chemokine signaling pathway | 4 | S | 0.007 |
5 | Rap1 signaling pathway | 3 | N | 3.71E-05 |
6 | ECM-receptor interaction | 3 | 0.472 | |
7 | Calcium signaling pathway | 2 | N | 4.95E-05 |
8 | Adrenergic signaling in cardiomyocytes | 1 | S | 0.014 |
9 | Melanoma | 1 | S | 3.00E-03 |
10 | Pathways in Cancer | 1 | S | 0.002 |
11 | Complement and coagulation cascades | 1 | S | 0.005 |
12 | Systemic lupus erythematosus | 1 | S | 0.002 |
13 | Colerectal cancer | 1 | 0.531 | |
14 | Small cell lung cancer | 1 | S | 0.015 |
15 | Endocrine and other factor-regulated calcium reabsorption | 1 | 0.183 | |
16 | Ras signal pathway | 1 | S | 0.038 |
17 | Prostate cancer | 1 | S | 0.004 |
18 | Maturity onset diabetes of the young | 1 | S | 0.047 |